• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Amgen's Prolia shows positive results

Amgen's Prolia shows positive results

March 29, 2011
CenterWatch Staff

Amgen has presented new long-term data showing that women with osteoporosis who have been treated with Prolia for up to five years experienced statistically significant, year-to-year increases in lumbar spine and total hip bone mineral density.

The 4,550-patient follow-up data, presented at the European Congress on Osteoporosis and Osteoarthritis in Valencia, Spain, showed treatment with Prolia (denosumab), a first-in-class, fully human monoclonal antibody designed to target RANK ligand, resulted in "robust BMD gains after five continuous years of treatment," i.e. 13.7% for lumbar spine BMD and 7.0% for total hip BMD.

In years four and five, women taking Prolia experienced further 1.9% and 1.7% increases in lumbar spine BMD and extra 0.7% and 0.6% increases in total hip BMD. Amgen also said the incidences of new osteoporotic fractures remained low for women taking Prolia for five years. Also, the women who transitioned from placebo to Prolia in the extension study showed significant BMD increases during the first two years of treatment: 7.9% in lumbar spine BMD and 4.1% in total hip BMD.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing